Marinomed Biotech Ag

Marinomed Biotechnologie Gmbh

Avir Green Hills Biotechnology Research Development Trade Ag

Nicox S.a.

Qasar Technologieentwicklung

Avir Green Hills Biotechnology Research Devlopment Trade Ag

Visufarma B.v.

Qasar Technologieentwicklung Ges.m.b.h.

Andreas Grassauer

Eva Prieschl-Grassauer

Christiane Koller

Thomas Muster

Angelika Bodenteich

Martina Morokutti-Kurz

Alexander Pretsch

Sabine Nakowitsch

Frédéric Pilotaz

Hubert Pehamberger

Marielle König-Schuster

Klaus Wolff

Marielle Konig-Schuster

Ernst Küchler

Frederic Pilotaz

Joachim Seipelt

Cornelia Kaintz

Manfred Hettmer

Elisabeth Gaudernak

Tobias Bartusch

Norbert Frischauf

Eva Prieschl

Christiane Meier

Philipp Graf

Martina Morokutti-kurz

Eva Prieschl-grassauer

Marielle KÖNIG-Schuster

A method of increasing the solubility of a water-insoluble or slightly water-soluble hydrophobic organic compound in an aqueous solvent includes adding a saponin component selected from escin, glycyrrhizin, andextract to the aqueous solvent in an amount sufficient to trigger the formation of micelles, wherein in a first step the hydrophobic organic compound is pre-dissolved in an organic solvent, and in a second step the organic solvent comprising the pre-dissolved compound is admixed to the aqueous solvent, whereby at least a part of the insoluble or slightly soluble hydrophobic organic compound gets solubilized and dissolved in the aqueous solvent, yielding an aqueous composition having an increased concentration of said organic compound dissolved therein. Also indicated are pharmaceutical or cosmetic compositions including a water-insoluble or slightly water-soluble organic compound dissolved in an aqueous solvent at substantially increased concentrations.

Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs

A pharmaceutical composition has a stuffy nose deblocking activity. The composition includes a hyperosmolar aqueous solution of a non-ionic osmolality adjusting agent, optionally in combination with an ionic osmolality adjusting agent, wherein the composition further includes iota-carrageenan and/or kappa-carrageenan as an active antiviral ingredient in an antivirally effective amount, with the proviso that the composition in its ready-for-use formulation contains no more than 0-1.5% w/v of the ionic osmolality adjusting agent. The composition is useful for deblocking a stuffy nose and for prophylactic or therapeutic intervention of a number of viral infections of the upper respiratory tract.

Stuffy nose deblocking composition having antiviral activity

Disclosed herein is a method of reducing the risk of a rhinovirus infection, the method includes administering to a subject a composition comprising iota-carrageenan in an antiviral effective amount as an active antiviral ingredient.

Antiviral composition and method of use

The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus. The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus.

Antiviral composition comprising a sulfated polysaccharide

The present invention relates to a pharmaceutical composition for use as a medicament in the prophylactic or therapeutic topical treatment of viral eye infections caused by adenovirus of subtype D or influenza A virus of subtype H7. The composition in its ready-for-use formulation comprises iota carrageenan as an active antiviral ingredient and is substantially free of a metal halide salt or contains no more than 0.5% w/v of a metal halide salt.

Composition effective against viral conjunctivitis

The present invention relates to iota- and/or kappa-carrageenan in combination with a neuraminidase inhibitor for use as a medicament in the prophylactic or therapeutic treatment of a symptom, condition or disease caused by or associated with an infection by an influenza virus.

Synergistic antiviral composition and use thereof

The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment diseases mediated or caused by activated granulocytes, preferably a type I or type III allergy or septic shock.

Use of escin

A method for manufacturing an antiviral pharmaceutical composition for the prophylaxis or treatment of a rhinovirus infection that includes the utilization of iota-, kappa- or lambda-carrageenan or mixtures thereof.

Nucleotide sequences and fragments which code for a human endogenous retrovirus which is infectious. 'Fragments' according to the present invention relate also to specific fragments of the sequences inserted into the vector pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt and MERV-pol as mentioned above. Additionally, methods of using such sequences, polypeptides encoded by such sequences, antibodies directs against such sequences, and methods and compositions relating to the same are all contemplated.

Polynucleotide fragments of an infectious human endogenous retrovirus

Described is a polynucleotide molecule being a fragment of a polynucleotide sequence of an infectious human endogenous retrovirus, said polynucleotide molecule comprising a sequence selected from the group consisting of (a) a sequence with at least 98%, preferably 99%, still preferred 99.5%, identity to a sequence according to SEQ ID No 1, (b) a sequence which hybridises under stringent conditions with a nucleotide sequence according to said SEQ ID No 1, (c) a sequence which differs from said sequences (a) or (b) due to degeneration of the genetic code and (d) a sequence comprising sequences inserted into vectors pCR4-Topo and deposited as 'MERV-env', 'MERV-gag', &#x201c;MERV-prt&#x201d; and &#x201c;MERV-pol&#x201d; at the DSMZ on 26 Sep. 2001 or fragments thereof.

The invention relates to a method and a device for generating Alfv&#xe9;n waves, in which ionizable material is provided that penetrates a magnetic field. In order to create such a method or a device in which material can be conveyed based on the Alfv&#xe9;n waves, the magnetic field consists of a primary magnetic field that is periodically deformed by at least one oscillating secondary magnetic field that is polarized in the opposite direction from the primary field such that Alfv&#xe9;n waves are created in the ionizable material located in said magnetic field. The Alfv&#xe9;n waves propagate at a speed that depends on the density of the material penetrating the magnetic field and the field intensity of the magnetic field. The field intensity of the magnetic field is greater than the kinetic energy of the material located in the magnetic field such that material is conveyed by means of the Alfv&#xe9;n waves.

Method and device for generating Alfv&#xe9;n waves

The invention discloses a use of dithiocarbamate compounds having the structural formula RRNCSH, in which Rand R, independently of each other, represent a straight or branched C-Calkyl, or, with the nitrogen atom, form an aliphatic ring with 4 to 6 C atoms, in which R, R, or the aliphatic ring is optionally substituted with one or more substituents selected from OH, NO, NH, COOH, SH, F, Cl, Br, I, methyl or ethyl, and oxidized forms of these compounds, in particular dimers thereof, as well as pharmaceutically acceptable salts thereof, to prepare an agent for treating or preventing an infection by RNA viruses which attack the respiratory tract and cause disease there.

Growing community of inventors

Vienna, Austria

Andreas Grassauer